Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             68 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases Halperin, Ilan
2009
6 1 p. 128-140
13 p.
artikel
2 Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases Halperin, Ilan
2009
6 1 p. 128-140
artikel
3 Break and poster viewing 2009
6 1 p. 203-
1 p.
artikel
4 Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia Kim, Dennis H.
2009
6 1 p. 78-85
8 p.
artikel
5 Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia Kim, Dennis H.
2009
6 1 p. 78-85
artikel
6 Contents 2009
6 1 p. A2-A3
nvt p.
artikel
7 Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs Millan, Mark J.
2009
6 1 p. 53-77
25 p.
artikel
8 Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Millan, Mark J.
2009
6 1 p. 53-77
artikel
9 Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease Petzer, Jacobus P.
2009
6 1 p. 141-151
artikel
10 Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A 2A Receptors for Parkinson's Disease Petzer, Jacobus P.
2009
6 1 p. 141-151
11 p.
artikel
11 Editorial Board 2009
6 1 p. A1-
1 p.
artikel
12 Keynote Address—GINA: Public Policy, Private Protection and Implications for Huntington Disease Maltby, Lewis
2009
6 1 p. 203-
1 p.
artikel
13 Keynote Address—The Pathway Forward for Development of New Treatments for Manifest and Premanifest Huntington Disease Katz, Russell
2009
6 1 p. 203-
1 p.
artikel
14 Keynote Address—Unmet Clinical Research Needs for Persons with Pre-Manifest Huntington Disease Sabine, Charles
2009
6 1 p. 202-
1 p.
artikel
15 Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease Bolognesi, Maria Laura
2009
6 1 p. 152-162
artikel
16 Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease Bolognesi, Maria Laura
2009
6 1 p. 152-162
11 p.
artikel
17 Metabotropic Glutamate Receptors as Targets for Multipotential Treatment of Neurological Disorders Byrnes, Kimberly R.
2009
6 1 p. 94-107
14 p.
artikel
18 Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders Byrnes, Kimberly R.
2009
6 1 p. 94-107
artikel
19 Multifunctional Actions of Approved and Candidate Stroke Drugs Minnerup, Jens
2009
6 1 p. 43-52
10 p.
artikel
20 Multifunctional actions of approved and candidate stroke drugs Minnerup, Jens
2009
6 1 p. 43-52
artikel
21 Multifunctional Drugs As Neurotherapeutics Van der Schyf, Cornelis J.
2009
6 1 p. 1-3
3 p.
artikel
22 Multifunctional drugs as neurotherapeutics Schyf, Cornelis J. Van der
2009
6 1 p. 1-3
artikel
23 Multifunctional Drugs for Head Injury Vink, Robert
2009
6 1 p. 28-42
15 p.
artikel
24 Multifunctional drugs for head injury Vink, Robert
2009
6 1 p. 28-42
artikel
25 Multifunctional Drug Treatment in Neurotrauma Stoica, Bogdan
2009
6 1 p. 14-27
14 p.
artikel
26 Multifunctional drug treatment in neurotrauma Stoica, Bogdan
2009
6 1 p. 14-27
artikel
27 Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs Weinreb, Orly
2009
6 1 p. 163-174
12 p.
artikel
28 Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs Weinreb, Orly
2009
6 1 p. 163-174
artikel
29 Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Silver, Henry
2009
6 1 p. 86-93
artikel
30 Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia? Silver, Henry
2009
6 1 p. 86-93
8 p.
artikel
31 Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System Buccafusco, Jerry J.
2009
6 1 p. 4-13
10 p.
artikel
32 Multifunctional receptor-directed drugs for disorders of the central nervous system Buccafusco, Jerry J.
2009
6 1 p. 4-13
artikel
33 Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets Li, Wenming
2009
6 1 p. 187-201
artikel
34 Novel Anti-Alzheimer's Dimer Bis(7)-Cognitin: Cellular and Molecular Mechanisms of Neuroprotection Through Multiple Targets Li, Wenming
2009
6 1 p. 187-201
15 p.
artikel
35 Platform Presentation—Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND) 2009
6 1 p. 203-
1 p.
artikel
36 Platform Presentation—Lifestyle Activity and the Age of Onset of Huntington Disease Trembath, K.
2009
6 1 p. 202-
1 p.
artikel
37 Platform Presentation—Longitudinal Structural MRI Data from PREDICT-HD: Striatal and Cortical Changes in Pre-Clinical HD Aylward, E.
2009
6 1 p. 202-203
2 p.
artikel
38 Platform Presentation—Loss of Striatal Dopaminergic Function and Thalamic Compensatory Mechanism During Phenocoversion of Preclinical Huntington's Disease Poston, K.L.
2009
6 1 p. 203-
1 p.
artikel
39 Polycyclic compounds: Ideal drug scaffolds for the design of multiple mechanism drugs? Schyf, Cornells J. Van der
2009
6 1 p. 175-186
artikel
40 Polycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs? Van der Schyf, Cornelis J.
2009
6 1 p. 175-186
12 p.
artikel
41 Poster 8: A Comparison of Two Brief Cognitive Instruments in Huntington Disease (HD) Corey-Bloom, J.
2009
6 1 p. 206-
1 p.
artikel
42 Poster 12: A Metabolic Network Associated with the Progression of Preclinical Huntington's Disease: Application of the Ordinal Trends Analysis to a Longitudinal PET Study Tang, C.
2009
6 1 p. 207-208
2 p.
artikel
43 Poster 3: An Examination of Actual and Potential Discrimination of Individuals at Risk of Huntington's Disease: An Analysis of the RESPOND-HD Data from Australia (Site 144) Goh, A.
2009
6 1 p. 204-205
2 p.
artikel
44 Poster 5: An Item Response Analysis of Depressive Symptomatology in Pre-Huntington Disease Vaccarino, A.
2009
6 1 p. 205-
1 p.
artikel
45 Poster 16: Antidepressant Use in PREDICT-HD: Patterns of Use Relevant to “Naturalistic” Drug Studies Rowe, K.
2009
6 1 p. 209-
1 p.
artikel
46 Poster 10: A Randomized, Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington's Disease Beglinger, L.J.
2009
6 1 p. 207-
1 p.
artikel
47 Poster 19: Basal Ganglia Pathology in Preclinical and Early Symptomatic Huntington's Disease: Diffusion Tensor Imaging, Magnetic Resonance Spectroscopy, and Volumetric Measures—Which Imaging Modality Is More Sensitive? Chua, P.
2009
6 1 p. 210-
1 p.
artikel
48 Poster 23: Characterization of Frontal Lobe Behavioral Syndromes in Huntington's Disease (HD) Oelke, L.
2009
6 1 p. 211-
1 p.
artikel
49 Poster 22: Cooperative Huntington Observational Research Trial (COHORT): Baseline Mental Health Risks 2009
6 1 p. 211-
1 p.
artikel
50 Poster 9: Corticostriatal Abnormalities in HD: A Combined Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging Study Weaver, K.E.
2009
6 1 p. 206-207
2 p.
artikel
51 Poster 14: Earliest Functional Declines in Huntington's Disease O'Rourke, J.F.
2009
6 1 p. 208-
1 p.
artikel
52 Poster 13: Early Diagnosis of Mitochondrial Dysfunction in Huntington's Disease In Vivo Conley, K.E.
2009
6 1 p. 208-
1 p.
artikel
53 Poster 24: Expert Treatment Preferences for the Motor, Mood, and Behavioral Symptoms of Huntington's Disease Veatch Goodman, L.
2009
6 1 p. 211-212
2 p.
artikel
54 Poster 21: Insurance Ownership and Genetic Risk Oster, E.
2009
6 1 p. 210-211
2 p.
artikel
55 Poster 17: Lifestyle Activity and the Age of Onset of Huntington Disease Trembath, K.
2009
6 1 p. 209-
1 p.
artikel
56 Poster 7: Memory for Temporal Sequences for the Early Detection of Cognitive Changes in Preclinical Huntington's Disease Pirogovsky, E.
2009
6 1 p. 206-
1 p.
artikel
57 Poster 11: Motor Symptom–Related Metabolic Network in Huntington's Disease Feigin, A.
2009
6 1 p. 207-
1 p.
artikel
58 Poster 20: Music, Meditation, and Huntington's Disease Pugliese, M.
2009
6 1 p. 210-
1 p.
artikel
59 Poster 15: Predicting Cognitive Decline: Another Method for Stratifying Samples? Duff, K.
2009
6 1 p. 208-209
2 p.
artikel
60 Poster 1: Survey of Clinical Trial Interest and Literacy in Huntington Support Groups: Northwest Pilot Project Goodman, L. Veatch
2009
6 1 p. 204-
1 p.
artikel
61 Poster 18: The Effects of Assistive Devices on Gait Measures in Huntington's Disease Kloos, A.D.
2009
6 1 p. 209-210
2 p.
artikel
62 Poster 4: The Functional Rating Scale Taskforce for Pre-Huntington's Disease: An Empirically-Driven Initiative for New Scale Development Evans, K.
2009
6 1 p. 205-
1 p.
artikel
63 Poster 2: The Involvement of Children in COHORT Quaid, K.
2009
6 1 p. 204-
1 p.
artikel
64 Poster 6: Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease Block, R.C.
2009
6 1 p. 205-206
2 p.
artikel
65 Poster viewing 2009
6 1 p. 202-
1 p.
artikel
66 Second Annual Huntington Disease Clinical Research Symposium Sabine, Charles
2009
6 1 p. 202-212
artikel
67 Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System Sirén, Anna-Leena
2009
6 1 p. 108-127
20 p.
artikel
68 Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system Sirén, Anna-Leena
2009
6 1 p. 108-127
artikel
                             68 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland